Survival benefits in non-small cell lung cancer during the immune checkpoint inhibitor era: integrating lymph node burden for prognostic precision.

Additionally, patients under 60 years of age, those receiving chemotherapy or radiotherapy, and those with higher N stages were more likely to derive OS or CSS benefits following ICI introduction (although some subgroup interaction did not reach statistical significance), which suggested potential therapeutic differences.

also in 111,027 other papers